Varenicline for smoking cessation

  • Technology appraisal guidance
  • TA123
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The evidence review group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR):

  • D Hind, P Tappenden, J Peters, K Kenjegalieva. Varenicline for smoking cessation: a single technology appraisal(March 2007).

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Companies or sponsors were also invited to make written submissions. Professional or specialist, and patient or carer groups, gave their expert views on varenicline by providing a written statement to the Committee. Companies or sponsors, and professional or specialist, and patient or carer groups, have the opportunity to appeal against the final appraisal determination.

Companies or sponsors:

  • Pfizer Ltd

Professional or specialist, and patient or carer groups:

  • Action Heart

  • British Heart Foundation

  • Burnley, Pendle and Rossendale PCT

  • Cancer Research UK

  • General Practice Airways Group

  • Macmillan Cancer Relief

  • National Lung Cancer Forum for Nurses

  • Primary Care Cardiovascular Society

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Physicians

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • British Society for Cardiovascular Research

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline (Bupropion)

  • GlaxoSmithKline Consumer Healthcare (Nicotine)

  • Medicines and Healthcare Products Regulatory Agency (MHRA)

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • School of Health and Related Research (ScHARR), University of Sheffield

The following individuals were selected from clinical specialist and patient advocate nominations from the professional or specialist, and patient or carer groups. They gave their expert personal view on varenicline by providing written evidence to the Committee.

  • Dr Katherine Willmer, Consultant Cardiologist, nominated by the British Cardiovascular Society – clinical specialist

  • Mrs Christine Owens, Head of Tobacco Control of and nominated by the Roy Castle Lung Cancer Foundation – patient expert

  • Mr David Geldard, President, Heart Care Partnership (UK), nominated by the British Cardiovascular Society – patient expert